Back to top
more

BioCardia (BCDA)

(Delayed Data from NSDQ)

$0.38 USD

0.38
29,340

+0.01 (2.34%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.39 +0.01 (3.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCDA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

BioCardia, Inc. [BCDA]

Reports for Purchase

Showing records 1 - 20 ( 57 total )

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 2

02/12/2024

Company Report

Pages: 4

Raises Capital but ItÂ’s Less Than a Million, Stock Back to Its Lows CardiAMP Trial Pushes Forward in the Wake of the Last Failed Trial

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 3

12/06/2023

Company Report

Pages: 4

Dilution is Better than Extinction - Sure

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 4

11/14/2023

Daily Note

Pages: 4

CardiAMP Heart Failure II Trial Gets the Green Light; Data Readout Expected in 4Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 5

11/09/2023

Company Report

Pages: 7

3Q23 Results; Awaiting Regulatory Decisions and Addressing Cash Resources; PMDA and FDA Updates Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 6

10/11/2023

Company Report

Pages: 8

High Level NT-proBNP Population is the Focus of the Anticipated New CardiAMP HF Trial II

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 7

09/06/2023

Company Report

Pages: 9

Unsatisfactory Phase 3 CardiAMP HF Interim Look; Potential New Trial With Modified Protocol; Target Reduced to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 8

09/05/2023

Company Report

Pages: 4

The 250-patient randomized controlled study is unlikely to meet its primary three-tiered FS efficacy endpoint

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 9

08/17/2023

Company Report

Pages: 4

Post DSMB Pausing Trial: Reports 2nd Qtr. Loss of $3.4M We Expect the Company to Raise Capital Again, soon

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 10

08/10/2023

Company Report

Pages: 8

2Q23 Results; All Efforts Into Cardiac Programs; Uncertain CardiAMP HF Path Forward in the U.S.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 11

07/24/2023

Company Report

Pages: 4

DSMB Recommends Trial be Paused

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 12

07/24/2023

Company Report

Pages: 8

DSMB Pauses CardiAMP HF Enrollment Pending 12-Month Outcomes Analysis For All Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 13

07/05/2023

Daily Note

Pages: 6

Submission of CardiAMP Cell Therapy to the PMDA Accomplished; Initial Feedback Expected September 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 14

06/22/2023

Company Report

Pages: 5

A Curious Press Release Followed by a Raise

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 15

06/21/2023

Company Report

Pages: 8

Adaptive SAP Aspires an Early CardiAMP HF Efficacy Readout; Upcoming DSMB Meeting Next Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 16

06/08/2023

Company Report

Pages: 4

First Quarter Results: $4.8M in Cash Remaining

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 17

05/11/2023

Company Report

Pages: 9

1Q23 Results; FDA Feedback on Revised CardiAMP HF Statistical Analysis Plan Nears

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 18

04/21/2023

Company Report

Pages: 4

Fourth Quarter Results: $7.4M in Cash Remaining

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 19

03/30/2023

Company Report

Pages: 9

2022 Results; CardiAMP HF Accumulates Signs of Cardiac Repair; Prepping for Pipeline Boost in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 20

03/07/2023

Company Report

Pages: 4

Announces echocardiography data from the Phase III CardiAMP Cell Therapy Heart Failure Trial at the American College of Cardiology, but N

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party